PDCD1 and lung cancer: Likewise, the low inhibitory effects (24.8%, P = 0.0821) or (37.6%, P = 0.0093) was achieved by oral administration of PD-1 or L.p R3 with regard to the tumor in LLC lung cancer mouse model.